Woodline Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History
Bought
Maintained
Sold
Other funds holding HZNP
IA
BTI
VWA
FSWA
BCMLT
HNB
Woodline Partners's HZNP Position: Q4 2023 in Review
Woodline Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 170,848 shares — an estimated $19.8M sold.
Woodline Partners first reported a position in HZNP in Q4 2019 and held it in 16 quarters. The position peaked at $144M in Q3 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.
- Woodline Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
- Woodline Partners sold 170,848 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $19.8M.
- Woodline Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 16 quarters.
- Woodline Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $144M in Q3 2022.
- 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.
Based on Woodline Partners's 13F filing for Q4 2023, filed 14 Feb 2024.